Amyloid β protein in plasma from patients with sporadic Alzheimer' s disease

Akira Tamaoka, Tetsuo Fukushima, Naoya Sawamura, Kin'ya Ishikawa, Eiichi Oguni, Yasuko Komatsuzaki, Shin'ichi Shoji

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Fibrillar amyloid β protein (Aβ) deposition is increased in the brains of patients with Alzheimer's disease (AD), and is manifested as senile plaques (SPs) and congophilic angiopathy (CA). Aβ40 and Aβ42(43), two chief species of Aβ, are documented in SPs and CA, as well as in cerebrospinal fluid (CSF) and cell culture media. Aβ42(43) is the major component of diffuse plaques, the earliest form of SPs. Thus, we hypothesized that determination of the amount of Aβ42(43) in CSF or plasma might provide a diagnostic laboratory test for AD. We measured amounts of different Aβ species in plasma from 28 patients with sporadic probable AD, 40 age-matched neurologic patients without dementia and 25 age-matched normal controls using enzyme-linked immunosorbent assays (ELISAs). Plasma concentrations of Aβ1-40 and Aβ1-42(43) did not significantly differ among these groups. These findings suggest the unlikelihood that plasma Aβ assays would be useful as a diagnostic tool for AD.

Original languageEnglish
Pages (from-to)65-68
Number of pages4
JournalJournal of the Neurological Sciences
Volume141
Issue number1-2
DOIs
Publication statusPublished - 1996 Sep 15
Externally publishedYes

Fingerprint

Amyloidogenic Proteins
Amyloid Plaques
Alzheimer Disease
Cerebral Amyloid Angiopathy
Cerebrospinal Fluid
Serum Amyloid A Protein
Routine Diagnostic Tests
Nervous System
Culture Media
Dementia
Cell Culture Techniques
Enzyme-Linked Immunosorbent Assay
Brain

Keywords

  • Alzheimer's disease
  • Amyloid β protein
  • Amyloid angiopathy
  • Enzyme-linked immunosorbent assay
  • Plasma
  • Senile plaque

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Amyloid β protein in plasma from patients with sporadic Alzheimer' s disease. / Tamaoka, Akira; Fukushima, Tetsuo; Sawamura, Naoya; Ishikawa, Kin'ya; Oguni, Eiichi; Komatsuzaki, Yasuko; Shoji, Shin'ichi.

In: Journal of the Neurological Sciences, Vol. 141, No. 1-2, 15.09.1996, p. 65-68.

Research output: Contribution to journalArticle

Tamaoka, A, Fukushima, T, Sawamura, N, Ishikawa, K, Oguni, E, Komatsuzaki, Y & Shoji, S 1996, 'Amyloid β protein in plasma from patients with sporadic Alzheimer' s disease', Journal of the Neurological Sciences, vol. 141, no. 1-2, pp. 65-68. https://doi.org/10.1016/0022-510X(96)00143-8
Tamaoka, Akira ; Fukushima, Tetsuo ; Sawamura, Naoya ; Ishikawa, Kin'ya ; Oguni, Eiichi ; Komatsuzaki, Yasuko ; Shoji, Shin'ichi. / Amyloid β protein in plasma from patients with sporadic Alzheimer' s disease. In: Journal of the Neurological Sciences. 1996 ; Vol. 141, No. 1-2. pp. 65-68.
@article{d26102ea733d4b059818127fc824ab69,
title = "Amyloid β protein in plasma from patients with sporadic Alzheimer' s disease",
abstract = "Fibrillar amyloid β protein (Aβ) deposition is increased in the brains of patients with Alzheimer's disease (AD), and is manifested as senile plaques (SPs) and congophilic angiopathy (CA). Aβ40 and Aβ42(43), two chief species of Aβ, are documented in SPs and CA, as well as in cerebrospinal fluid (CSF) and cell culture media. Aβ42(43) is the major component of diffuse plaques, the earliest form of SPs. Thus, we hypothesized that determination of the amount of Aβ42(43) in CSF or plasma might provide a diagnostic laboratory test for AD. We measured amounts of different Aβ species in plasma from 28 patients with sporadic probable AD, 40 age-matched neurologic patients without dementia and 25 age-matched normal controls using enzyme-linked immunosorbent assays (ELISAs). Plasma concentrations of Aβ1-40 and Aβ1-42(43) did not significantly differ among these groups. These findings suggest the unlikelihood that plasma Aβ assays would be useful as a diagnostic tool for AD.",
keywords = "Alzheimer's disease, Amyloid β protein, Amyloid angiopathy, Enzyme-linked immunosorbent assay, Plasma, Senile plaque",
author = "Akira Tamaoka and Tetsuo Fukushima and Naoya Sawamura and Kin'ya Ishikawa and Eiichi Oguni and Yasuko Komatsuzaki and Shin'ichi Shoji",
year = "1996",
month = "9",
day = "15",
doi = "10.1016/0022-510X(96)00143-8",
language = "English",
volume = "141",
pages = "65--68",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Amyloid β protein in plasma from patients with sporadic Alzheimer' s disease

AU - Tamaoka, Akira

AU - Fukushima, Tetsuo

AU - Sawamura, Naoya

AU - Ishikawa, Kin'ya

AU - Oguni, Eiichi

AU - Komatsuzaki, Yasuko

AU - Shoji, Shin'ichi

PY - 1996/9/15

Y1 - 1996/9/15

N2 - Fibrillar amyloid β protein (Aβ) deposition is increased in the brains of patients with Alzheimer's disease (AD), and is manifested as senile plaques (SPs) and congophilic angiopathy (CA). Aβ40 and Aβ42(43), two chief species of Aβ, are documented in SPs and CA, as well as in cerebrospinal fluid (CSF) and cell culture media. Aβ42(43) is the major component of diffuse plaques, the earliest form of SPs. Thus, we hypothesized that determination of the amount of Aβ42(43) in CSF or plasma might provide a diagnostic laboratory test for AD. We measured amounts of different Aβ species in plasma from 28 patients with sporadic probable AD, 40 age-matched neurologic patients without dementia and 25 age-matched normal controls using enzyme-linked immunosorbent assays (ELISAs). Plasma concentrations of Aβ1-40 and Aβ1-42(43) did not significantly differ among these groups. These findings suggest the unlikelihood that plasma Aβ assays would be useful as a diagnostic tool for AD.

AB - Fibrillar amyloid β protein (Aβ) deposition is increased in the brains of patients with Alzheimer's disease (AD), and is manifested as senile plaques (SPs) and congophilic angiopathy (CA). Aβ40 and Aβ42(43), two chief species of Aβ, are documented in SPs and CA, as well as in cerebrospinal fluid (CSF) and cell culture media. Aβ42(43) is the major component of diffuse plaques, the earliest form of SPs. Thus, we hypothesized that determination of the amount of Aβ42(43) in CSF or plasma might provide a diagnostic laboratory test for AD. We measured amounts of different Aβ species in plasma from 28 patients with sporadic probable AD, 40 age-matched neurologic patients without dementia and 25 age-matched normal controls using enzyme-linked immunosorbent assays (ELISAs). Plasma concentrations of Aβ1-40 and Aβ1-42(43) did not significantly differ among these groups. These findings suggest the unlikelihood that plasma Aβ assays would be useful as a diagnostic tool for AD.

KW - Alzheimer's disease

KW - Amyloid β protein

KW - Amyloid angiopathy

KW - Enzyme-linked immunosorbent assay

KW - Plasma

KW - Senile plaque

UR - http://www.scopus.com/inward/record.url?scp=0030587520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030587520&partnerID=8YFLogxK

U2 - 10.1016/0022-510X(96)00143-8

DO - 10.1016/0022-510X(96)00143-8

M3 - Article

VL - 141

SP - 65

EP - 68

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -